Gossamer Bio FY2028 EPS Forecast Lifted by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at HC Wainwright upped their FY2028 earnings per share estimates for Gossamer Bio in a report issued on Monday, June 1st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.13) per share for the year, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at ($0.06) EPS.

A number of other research analysts have also recently issued reports on the company. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th. Oppenheimer decreased their target price on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. Wedbush reissued a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Gossamer Bio Trading Up 1.1%

NASDAQ GOSS opened at $0.20 on Wednesday. Gossamer Bio has a 12 month low of $0.16 and a 12 month high of $3.87. The company has a market capitalization of $46.99 million, a PE ratio of -0.25 and a beta of 2.00. The stock has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $1.66.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.96 million during the quarter, compared to analyst estimates of $4.67 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in shares of Gossamer Bio during the second quarter worth about $26,000. Banco BTG Pactual S.A. acquired a new position in shares of Gossamer Bio during the second quarter worth about $27,000. MMA Asset Management LLC acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $31,000. Soltis Investment Advisors LLC acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $31,000. Finally, Beacon Pointe Advisors LLC acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $34,000. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.